136 related articles for article (PubMed ID: 17541273)
1. Mechanism for the differentiation of EoL-1 cells into eosinophils by histone deacetylase inhibitors.
Kaneko M; Ishihara K; Takahashi A; Hong J; Hirasawa N; Zee O; Ohuchi K
Int Arch Allergy Immunol; 2007; 143 Suppl 1():28-32. PubMed ID: 17541273
[TBL] [Abstract][Full Text] [Related]
2. Mechanism for the decrease in the FIP1L1-PDGFRalpha protein level in EoL-1 cells by histone deacetylase inhibitors.
Ishihara K; Kaneko M; Kitamura H; Takahashi A; Hong JJ; Seyama T; Iida K; Wada H; Hirasawa N; Ohuchi K
Int Arch Allergy Immunol; 2008; 146 Suppl 1():7-10. PubMed ID: 18504399
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of eosinophilic leukemia EoL-1 cells into eosinophils induced by histone deacetylase inhibitors.
Ishihara K; Takahashi A; Kaneko M; Sugeno H; Hirasawa N; Hong J; Zee O; Ohuchi K
Life Sci; 2007 Mar; 80(13):1213-20. PubMed ID: 17258775
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms for the proliferation of eosinophilic leukemia cells by FIP1L1-PDGFRalpha.
Ishihara K; Kitamura H; Hiraizumi K; Kaneko M; Takahashi A; Zee O; Seyama T; Hong J; Ohuchi K; Hirasawa N
Biochem Biophys Res Commun; 2008 Feb; 366(4):1007-11. PubMed ID: 18086564
[TBL] [Abstract][Full Text] [Related]
5. Possible mechanism of action of the histone deacetylase inhibitors for the induction of differentiation of HL-60 clone 15 cells into eosinophils.
Ishihara K; Hong J; Zee O; Ohuchi K
Br J Pharmacol; 2004 Jul; 142(6):1020-30. PubMed ID: 15210580
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation.
Buitenhuis M; Verhagen LP; Cools J; Coffer PJ
Cancer Res; 2007 Apr; 67(8):3759-66. PubMed ID: 17440089
[TBL] [Abstract][Full Text] [Related]
7. Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.
Sadovnik I; Lierman E; Peter B; Herrmann H; Suppan V; Stefanzl G; Haas O; Lion T; Pickl W; Cools J; Vandenberghe P; Valent P
Exp Hematol; 2014 Apr; 42(4):282-293.e4. PubMed ID: 24407160
[TBL] [Abstract][Full Text] [Related]
8. Eosinophil cell lines.
Ishihara K
Methods Mol Biol; 2014; 1178():45-51. PubMed ID: 24986606
[TBL] [Abstract][Full Text] [Related]
9. Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL.
Li B; Zhang G; Li C; He D; Li X; Zhang C; Tang F; Deng X; Lu J; Tang Y; Li R; Chen Z; Duan C
PLoS One; 2012; 7(4):e34912. PubMed ID: 22523564
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.
Baumgartner C; Gleixner KV; Peter B; Ferenc V; Gruze A; Remsing Rix LL; Bennett KL; Samorapoompichit P; Lee FY; Pickl WF; Esterbauer H; Sillaber C; Superti-Furga G; Valent P
Exp Hematol; 2008 Oct; 36(10):1244-53. PubMed ID: 18619723
[TBL] [Abstract][Full Text] [Related]
11. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
Cools J; Quentmeier H; Huntly BJ; Marynen P; Griffin JD; Drexler HG; Gilliland DG
Blood; 2004 Apr; 103(7):2802-5. PubMed ID: 14630792
[TBL] [Abstract][Full Text] [Related]
12. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.
Lierman E; Michaux L; Beullens E; Pierre P; Marynen P; Cools J; Vandenberghe P
Leukemia; 2009 May; 23(5):845-51. PubMed ID: 19212337
[TBL] [Abstract][Full Text] [Related]
13. The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus.
Burgstaller S; Kreil S; Waghorn K; Metzgeroth G; Preudhomme C; Zoi K; White H; Cilloni D; Zoi C; Brito-Babapulle F; Walz C; Reiter A; Cross NC
Leukemia; 2007 Dec; 21(12):2428-32. PubMed ID: 17914408
[TBL] [Abstract][Full Text] [Related]
14. FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells.
Fukushima K; Matsumura I; Ezoe S; Tokunaga M; Yasumi M; Satoh Y; Shibayama H; Tanaka H; Iwama A; Kanakura Y
J Biol Chem; 2009 Mar; 284(12):7719-32. PubMed ID: 19147501
[TBL] [Abstract][Full Text] [Related]
15. [Identification of FIP1L1-PDGFRA fusion, and expression of signal transducer and activator of transcription 5 in hypereosinophilic syndrome].
Zhang GS; Li B; Pei MF; Dai CW; Zheng WL; Shen JK
Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(18):1541-4. PubMed ID: 15500716
[TBL] [Abstract][Full Text] [Related]
16. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia.
Cools J; Stover EH; Wlodarska I; Marynen P; Gilliland DG
Curr Opin Hematol; 2004 Jan; 11(1):51-7. PubMed ID: 14676627
[TBL] [Abstract][Full Text] [Related]
17. Triptolide abrogates oncogene FIP1L1-PDGFRalpha addiction and induces apoptosis in hypereosinophilic syndrome.
Jin Y; Chen Q; Lu Z; Chen B; Pan J
Cancer Sci; 2009 Nov; 100(11):2210-7. PubMed ID: 19671059
[TBL] [Abstract][Full Text] [Related]
18. Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin.
Jin Y; Ding K; Li H; Xue M; Shi X; Wang C; Pan J
Mol Cancer; 2014 Jan; 13():17. PubMed ID: 24472312
[TBL] [Abstract][Full Text] [Related]
19. Oncostatin M is a FIP1L1/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia.
Hoermann G; Cerny-Reiterer S; Sadovnik I; Müllauer L; Bilban M; Gröger M; Horny HP; Reiter A; Schmitt-Graeff A; Mannhalter C; Valent P; Mayerhofer M
Allergy; 2013 Jun; 68(6):713-23. PubMed ID: 23621172
[TBL] [Abstract][Full Text] [Related]
20. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
